Activation-induced cell death in CAR-T cell therapy

Area of Science:

• Immunology
• Cell Biology
• Oncology

Background:

• Engineered T cells, known as chimeric antigen receptor (CAR)-T cells, have revolutionized hematologic cancer treatment.
• However, their efficacy against solid tumors is limited by poor CAR-T cell persistence.
• T cell death, particularly activation-induced cell death (AICD), is a key factor hindering CAR-T cell effectiveness in solid tumors.

Purpose of the Study:

• To elucidate the molecular mechanisms underlying AICD in CAR-T cells.
• To review current strategies aimed at overcoming AICD and enhancing CAR-T cell persistence.
• To provide insights for improving CAR-T cell therapy against solid tumors.

Main Methods:

• Review of existing literature on CAR-T cell therapy, AICD, and anti-apoptotic strategies.
• Analysis of molecular pathways involved in T cell activation and death.
• Synthesis of data on therapeutic approaches to mitigate AICD in CAR-T cells.

Main Results:

• Repeated antigen stimulation significantly triggers AICD in CAR-T cells.
• AICD is characterized by increased expression of death receptors and reduced T cell survival.
• Various genetic and pharmacological modifications are being explored to enhance CAR-T cell resistance to apoptosis.

Conclusions:

• Understanding AICD mechanisms is critical for advancing CAR-T cell therapy for solid tumors.
• Developing strategies to inhibit AICD can improve CAR-T cell persistence and anti-tumor activity.
• Further research into anti-AICD approaches holds significant potential for enhancing CAR-T cell efficacy in challenging solid tumor environments.